Skip to content

All Eyes on PCS - Analysis of the Retinal Microvasculature in Patients With Post-COVID-19 Syndrome

All Eyes on PCS - Analysis of the Retinal Microvasculature in Patients With Post-COVID-19 Syndrome

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05635552
Enrollment
300
Registered
2022-12-02
Start date
2022-10-17
Completion date
2023-07-21
Last updated
2022-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long Covid19, Post COVID-19 Condition, Endothelial Dysfunction

Keywords

Retinal Vessel Analysis, Retinal microvasculature, Autoimmunity, Inflammation, Vasculopathy

Brief summary

The goal of this observational, prospective study is to in depth analyze the retinal microvasculature in patients with Post-COVID-19 Syndrome (PCS). The main questions it aims to answer is: Do patients with PCS show a prolonged endothelial dysfunction when compared with fully COVID-19 recovered participants? Does symptom severity in PCS patients correlate with the extend of endothelial dysfunction? Do these changes correlate with improvement in symptoms in the prospective observation?

Detailed description

The investigators will recruit patients with PCS, fully COVID-19 recovered participants and COVID-19 infection naïve participants. After comprehensive clarification and given written informed consent, measurements will take place in the Klinikum rechts der Isar. To evaluate the retinal microvasculature dynamic retinal vessel analysis (DVA) and optical coherence tomography (OCT) are used. Patient reported outcomes (PROM) of PCS typical symptoms will be collected using standardized questionnaires. To ensure data quality the investigators will use standard operating procedures (SOP) for both technical measurements and data collection. For DVA measurements all examiners will be trained by a single experienced supervisor and must reach high image accuracy and quality in at least 10 volunteers. Examiners are only involved in data acquisition.

Interventions

DIAGNOSTIC_TESTHandgrip strength test

Measure the maximum isometric strength of the hand and forearm muscles and their fatiguability.

DVA is an established, non-invasive tool to measure the responsiveness of retinal vessels to flickering light. In addition static retinal vessel parameters are recorded.

DIAGNOSTIC_TESTOptical coherence tomography (OCT)

OCT is an imaging technique which applies low-coherence light to capture high resolution images from the ocular fundus.

Blood sample collection for clinical chemistry and isolation of PBMCs for FACS analysis.

The questionnaires evaluate anxiety, depression, chronic fatigue, quality of life, and post-covid typical symptoms

Sponsors

Ludwig-Maximilians - University of Munich
CollaboratorOTHER
Technical University of Munich
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients with Post-COVID syndrome (positive PCR or positive rapid antibody test ≥3 months) with a currently existing, PCS-typical complaint complex, ongoing for at least 2 months and cannot be explained by an alternative diagnosis. * Control group: recovered from COVID-19 infection (positive PCR or positive rapid antibody test ≥ 3 months) without residual symptoms. * Healthy cohort: no history of COVID-19 infection

Exclusion criteria

* Missing or incomplete consent form * Age \< 18 years * Pregnancy * Malignancy * Diseases associated with a significant change in life expectancy * Autoimmune diseases of the rheumatological type * Cataract * Epilepsy * Glaucoma

Design outcomes

Primary

MeasureTime frameDescription
PCS patients show an impaired retinal vessel responsiveness when compared with fully recovered COVID-19 participants.BaselineStatic and dynamic parameters of the retinal vessel analysis.

Secondary

MeasureTime frameDescription
PCS patients with improved symptoms show a change in retinal vessel responsiveness after 6 months when compared with baseline parameters.Baseline to month 6Static and dynamic parameters of the retinal vessel analysis. Test items of the The COVID-19 Yorkshire Rehabilitation Scale (C19-YRS) and PCS questionnaire. Calculation of PCS severity scores (Bahmer, 2022) in each patient with a range of score values from zero (better outcome) to 59 (worse outcome). Comparison of retinal vessel parameters and PCS scores between Baseline and month 6.
Symptom severity of PCS in patients correlates with impaired retinal vessel responsiveness.BaselineCorrelation between PCS severity scores with static and dynamic parameters of the retinal vessel analysis.
PCS patients with impaired RVA analysis show elevated levels of markers of endothelial dysfunction and of chronic inflammation when compared with COVID-19 recovered cohort.BaselineMeasurement of markers of endothelial dysfunction: Concentration of: sICAM, sVCAM, Thrombomodulin, P-Selectin,E-Selectin, ADMA, SADMA, Endothelin-1, ACE-1, ACE-2, ANG-2, GDF-15. Measurement of markers of chronic inflammation Concentration of IFN-β, IFN-λ1,TNFa. Comparison of marker levels to the COVID-19 recovered cohort.
PCS patients show an impaired retinal vessel responsiveness at baseline when compared with infection naïve participants.BaselineStatic and dynamic parameters of the retinal vessel analysis.
Characterization of immune cell composition in PCS patients and comparison with COVID-19 recovered and COVID-19 infection naïve participants.BaselineUsing flow cytometry to detect different T-cell and monocyte subpopulations.
PCS patients show a decrease in vessel density in OCT-A when compared with COVID-19 recovered participants.BaselineParameters of OCT-A.
PCS patients with impaired RVA show a reactivation of EBV.BaselineUsing PCR to measure EBV reactivation in patients plasma .

Countries

Germany

Contacts

Primary ContactChristoph Schmaderer, Prof. Dr.
christoph.schmaderer@mri.tum.de089 4140 5053
Backup ContactTimon Kuchler
timon.kuchler@mri.tum.de089 4140 8189

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026